Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumab

被引：64
|
作者：
Cousin, S. [1 ,2 ]
Toulmonde, M. [1 ,2 ]
Kind, M. [3 ]
Cazeau, A. -L. [4 ]
Bechade, D. [2 ]
Coindre, J. -M. [5 ]
Italiano, A. [1 ,2 ]
机构：
[1] Inst Bergonie, Early Phase Trials Unit, Bordeaux, France
[2] Inst Bergonie, Dept Med, Bordeaux, France
[3] Inst Bergonie, Dept Radiol, Bordeaux, France
[4] Inst Bergonie, Dept Nucl Med, Bordeaux, France
[5] Inst Bergonie, Dept Pathol, Bordeaux, France
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷 / 06期
关键词：
METASTATIC MELANOMA; IPILIMUMAB; PATIENT;
D O I：
10.1093/annonc/mdw125
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1178 / 1179
页数：2
相关论文
共 50 条
  • [31] A Case of Pembrolizumab (Anti-PD-1) Induced Encephalitis
    Zahid, Anza
    Poursheykhi, Meryim
    Saeed, Mujtaba
    Tremont, Ivo
    NEUROLOGY, 2022, 99 (23) : S72 - S73
  • [32] Predicting the anti-PD1 response
    Minton, Kirsty
    NATURE REVIEWS IMMUNOLOGY, 2019, 19 (07) : 414 - 415
  • [33] Predicting the anti-PD1 response
    Kirsty Minton
    Nature Reviews Immunology, 2019, 19 : 414 - 415
  • [34] Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810
    Falchook, Gerald S.
    Leidner, Rom
    Stankevich, Elizabeth
    Piening, Brian
    Bifulco, Carlo
    Lowy, Israel
    Fury, Matthew G.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
  • [35] Anti-PD-1 monoclonal antibody Cancer immunotherapy
    da Silva, R. Moreira
    DRUGS OF THE FUTURE, 2014, 39 (01) : 15 - 24
  • [36] Radiation Recall Pneumonitis Induced by Anti-PD-L1 Monoclonal Antibody Durvalumab
    Adunse, J. U.
    Kalifa, M.
    Assaly, R. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [37] UPDATED CLINICAL EFFICACY OF THE ANTI-PD-1 MONOCLONAL ANTIBODY PEMBROLIZUMAB (MK-3475) IN 411 PATIENTS WITH MELANOMA
    Ribas, A.
    Wolchok, J. D.
    Robert, C.
    Kefford, R.
    Hamid, O.
    Daud, A.
    Hwu, W-J.
    Weber, J. S.
    Joshua, A. M.
    Gangadhar, T. C.
    Patnaik, A.
    Hersey, P.
    Dronca, R.
    Zarour, H.
    Gergich, K.
    Lindia, J. A.
    Giannotti, M.
    Li, X. N.
    Ebbinghaus, S.
    Kang, S. P.
    Hodi, F. S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : E24 - E24
  • [38] Detailed safety profile of the anti-PD-1 monoclonal antibody pembrolizumab in 78 consecutive patients (pts) with advanced melanoma
    Boutros, C.
    Routier, E.
    Hua, C.
    Texier, M.
    Mateus, C.
    Libenciuc, C.
    Reigneau, M.
    Benannoune, N.
    Roy, S.
    Lanoy, E.
    Le Pavec, J.
    Ladurie, F. L.
    Carbonnel, F.
    Lambotte, O.
    Izzedine, H.
    Berdelou, A.
    Champiat, S.
    Soria, J-C.
    Eggermont, A.
    Robert, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [39] Monoclonal antibody targeting CEACAM1 enhanced the response to anti-PD1 immunotherapy in non-small cell lung cancer
    Zhao, Lianqi
    Li, Tingting
    Zhou, Yinwei
    Wang, Pengbo
    Luo, Lin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 143
  • [40] Systemic lupus erythematosus onset in patient receiving anti-PD1 treatment with pembrolizumab: a case report
    Ceccarelli, Fulvia
    Mancuso, Silvia
    Lucchetti, Ramona
    Conti, Fabrizio
    RHEUMATOLOGY, 2021, 60 (02) : E39 - E40
12345